Bispecific antibodies continue to show significant and impressive therapeutic value. While the development of bispecific antibodies is an evolving field, many challenges are still awaiting to be solved by experts in the field including target selection, better understanding of their mechanism of action, along with the combination selection of targets. CHI’s Second Annual Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific development to improve your candidates’ translatability into the clinic.

Preliminary Agenda

NK CELL AND T CELL ENGAGERS

Current Landscape of NK Cell and T Cell Engagers

G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology

TriKE-Based Combinatorial Therapy for Pancreatic Ductal Adenocarcinoma.

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School

A Novel T-Cell Engaging Bispecific Antibody Platform: Maximizing Tumor Cell Lysis While Minimizing Cytokine Toxicity and T Cell Exhaustion

Nathan Trinklein, PhD, Vice President, Discovery Research, Teneobio

Enhancing Safety and Efficacy for Bispecific T Cell Engager (BiTE®) Antibody

Tara Arvedson, PhD, Director, Oncology Research, Amgen

ENGINEERING INNOVATIONS FOR BI- AND MULTI-SPECIFIC PLATFORMS

Bi-Specific Antibodies - Platform Approaches to Rapidly Generate Binder- and Format Variability and New Functionalities

Ulrich Brinkmann, PhD, Expert Scientist, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, FRG

Concept to Clinic: Development of Fc-Containing XmAb® Bispecific Antibodies for Immunotherapy

Umesh S. Muchhal, PhD, Director, Protein Sciences, Xencor Inc

A Novel Platform for the Generation of Multivalent and Multispecific Ig-Like Molecules

Oliver Seifert, PhD, Senior Scientist, Institute of Cell Biology and Immunology, University of Stuttgart

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Shelley Force Aldred, PhD, VP, Preclinical Development, TeneoBio, Inc.

Leveraging its Format Flexibility to Engineer Anticalin Based Multi-Specifics in Immuno-Oncology

Stefan Grüner, PhD, Scientist, Protein Engineering, Pieris




For more details on the conference, please contact:
Emily Le

Conference Producer

[Cambridge Healthtech Institute]

Phone: 781-247-1812
Email: ele@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K

Jason Gerardi

Senior Manager, Business Development

[Cambridge Healthtech Institute]

Phone: 781-972-5452
Email: jgerardi@healthtech.com

 

Companies L-Z

Carol Dinerstein

Senior Manager, Business Development

[Cambridge Healthtech Institute]

Phone: 781-972-5471
Email: dinerstein@healthtech.com

 

 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag

Register